You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 16, 2025

Ucb Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Ucb Inc
International Patents:508
US Patents:36
Tradenames:29
Ingredients:24
NDAs:42
Drug Master File Entries: 1
Patent Litigation for Ucb Inc: See patent lawsuits for Ucb Inc

Drugs and US Patents for Ucb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ucb Inc VIMPAT lacosamide SOLUTION;INTRAVENOUS 022254-001 Oct 28, 2008 AP RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-006 Apr 2, 2012 RX Yes No 8,246,980 ⤷  Try for Free Y ⤷  Try for Free
Ucb Inc KEMSTRO baclofen TABLET, ORALLY DISINTEGRATING;ORAL 021589-002 Oct 30, 2003 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-005 Apr 2, 2012 RX Yes No 8,246,979 ⤷  Try for Free Y ⤷  Try for Free
Ucb Inc ZILBRYSQ zilucoplan sodium SOLUTION;SUBCUTANEOUS 216834-001 Oct 17, 2023 RX Yes Yes 11,965,040 ⤷  Try for Free Y ⤷  Try for Free
Ucb Inc AMITRIPTYLINE HYDROCHLORIDE amitriptyline hydrochloride TABLET;ORAL 086335-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-005 Apr 2, 2012 RX Yes No 8,246,980 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Ucb Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc KEMSTRO baclofen TABLET, ORALLY DISINTEGRATING;ORAL 021589-001 Oct 30, 2003 6,024,981 ⤷  Try for Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-004 Apr 2, 2012 7,413,747 ⤷  Try for Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-006 Apr 2, 2012 8,617,591 ⤷  Try for Free
Ucb Inc VIMPAT lacosamide SOLUTION;ORAL 022255-001 Apr 20, 2010 RE38551 ⤷  Try for Free
Ucb Inc VIMPAT lacosamide TABLET;ORAL 022253-004 Oct 28, 2008 5,654,301 ⤷  Try for Free
Ucb Inc NIRAVAM alprazolam TABLET, ORALLY DISINTEGRATING;ORAL 021726-002 Jan 19, 2005 6,024,981 ⤷  Try for Free
Ucb Inc NEUPRO rotigotine FILM, EXTENDED RELEASE;TRANSDERMAL 021829-003 May 9, 2007 6,699,498 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for UCB INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Oral Solution 10 mg/mL ➤ Subscribe 2012-10-29
➤ Subscribe Injection 10 mg/mL, 20 mL ➤ Subscribe 2016-06-30
➤ Subscribe Orally Disintegrating Tablets 0.25 mg, 0.5 mg, 1 mg and 2 mg ➤ Subscribe 2005-12-27
➤ Subscribe Tablets 1000 mg ➤ Subscribe 2007-01-24
➤ Subscribe Tablets 50 mg, 100 mg, 150 mg, and 200 mg ➤ Subscribe 2012-10-29
➤ Subscribe Extended-release Tablets 1000 mg ➤ Subscribe 2011-01-07
➤ Subscribe Tablets 7.5mg/12.5mg 15 mg/25 mg and 15 mg/12.5 mg ➤ Subscribe 2004-01-15
➤ Subscribe Extended-release Transdermal Film 1 mg/24 hr, 2 mg/24 hr, 3 mg/24 hr,4 mg/24 hr,6 mg/24 hr, and 8 mg/24 hr ➤ Subscribe 2013-11-26

Supplementary Protection Certificates for Ucb Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3154561 CR 2024 00021 Denmark ⤷  Try for Free PRODUCT NAME: ZILUCOPLAN; REG. NO/DATE: EU/1/23/1764 20231204
3154561 301275 Netherlands ⤷  Try for Free PRODUCT NAME: ZILUCOPLAN; REGISTRATION NO/DATE: EU/1/23/1764 20231204
1265862 PA2016013 Lithuania ⤷  Try for Free PRODUCT NAME: BRIVARACETAMAS; REGISTRATION NO/DATE: EU/1/15/1073 20160114
1452524 1690009-4 Sweden ⤷  Try for Free PRODUCT NAME: BRIVARACETAM; REG. NO/DATE: EU/1/15/1073 20150114
3154561 LUC00343 Luxembourg ⤷  Try for Free PRODUCT NAME: ZILUCOPLAN; AUTHORISATION NUMBER AND DATE: EU/1/23/1764 20231204
1452524 10/2016 Austria ⤷  Try for Free PRODUCT NAME: BRIVARACETAM; REGISTRATION NO/DATE: EU/1/15/1073 (MITTEILUNG) 20160118
0502314 SPC/GB02/037 United Kingdom ⤷  Try for Free PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: UCB Inc – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, UCB Inc stands out as a global biopharmaceutical leader with a strong focus on creating innovative solutions for patients living with severe neurological and immunological disorders. This comprehensive analysis delves into UCB's market position, strengths, and strategic insights, providing valuable information for industry professionals and investors alike.

UCB Inc: A Brief Overview

UCB Inc, headquartered in Belgium, has established itself as a prominent player in the pharmaceutical sector since its inception in 1928. With operations spanning nearly 40 countries and a workforce of approximately 9,000 employees, UCB has consistently demonstrated its commitment to improving the lives of patients worldwide[2].

Core Focus Areas

UCB's primary focus lies in two key therapeutic areas:

  1. Neurology
  2. Immunology

This specialization has allowed the company to develop a robust portfolio of innovative treatments and maintain a competitive edge in these niche markets[5].

UCB's Market Position

UCB has carved out a significant position in the global pharmaceutical market, particularly in its core therapeutic areas. The company's market share in its primary focus areas stands at approximately 5.1%, indicating a strong presence despite fierce competition from industry giants like Pfizer, Novartis, and Amgen[1].

Revenue Breakdown

In 2022, UCB reported total revenues of €5.6 billion, representing a year-over-year growth of 9% compared to €5.1 billion in 2021[1]. This growth can be attributed to increased sales of core products and the expansion of its portfolio.

The revenue breakdown by therapeutic area is as follows:

Revenue Source Amount (€ million) Percentage of Total Revenue
Neurology Products 3,200 57%
Immunology Products 1,800 32%
Other Revenue 600 11%

Geographical Revenue Distribution

UCB's global presence is reflected in its revenue distribution across different regions:

Region Revenue (€ million) Percentage of Total Revenue
Europe 3,000 54%
North America 2,200 39%
Rest of World 400 7%

The North American market has been particularly lucrative for UCB, with revenue growth of 11% year-over-year, attributed to increased demand and expanded market access for several key products[1].

UCB's Key Strengths

UCB's success in the competitive pharmaceutical landscape can be attributed to several key strengths:

1. Strong Product Portfolio

UCB boasts a diverse and robust product portfolio, with several blockbuster drugs contributing significantly to its revenue. Key products include:

  • Cimzia (immunology)
  • Vimpat (epilepsy)
  • Keppra (epilepsy)
  • Neupro (Parkinson's disease and restless leg syndrome)
  • Briviact (epilepsy)
  • Bimzelx (psoriasis)
  • Evenity (osteoporosis)
  • Nayzilam (cluster seizures)
  • Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome)[10]

2. Focus on Innovation

UCB's commitment to research and development is evident in its substantial R&D investment. In 2022, the company allocated €1.29 billion to R&D, representing about 32% of total revenue[1]. This significant investment positions UCB well for future growth and innovation.

3. Strategic Partnerships

UCB has actively pursued strategic partnerships to enhance its research capabilities and expand its product pipeline. For instance, in 2023, UCB announced a collaboration with Provention Bio to co-develop therapies for autoimmune diseases[1].

4. Strong Financial Performance

UCB has demonstrated solid financial performance, with a gross margin of 76% in 2022, indicating robust profitability that supports reinvestment into growth opportunities[1].

"UCB's focus on innovation, market expansion, strategic partnerships, and established competitive advantages position the company to capture future growth effectively, ensuring strong investor interest moving forward."[1]

Strategic Insights

UCB's strategic approach to maintaining and enhancing its market position is multifaceted:

1. Focus on Niche Markets

By concentrating on neurology and immunology, UCB has established a strong presence in these niche markets. This focused approach allows the company to develop deep expertise and build strong relationships with healthcare providers[5].

2. Emphasis on Patient-Centric Solutions

UCB's tagline, "Aspiring to be patient centric biopharma leader," underscores its commitment to developing solutions that directly address patient needs[5]. This patient-centric approach not only drives innovation but also enhances brand loyalty.

3. Global Expansion

UCB is actively pursuing opportunities in emerging markets, where demand for innovative therapies is increasing. The company reported an overall revenue growth of 8% in 2022, largely due to expansion into regions like Asia and Latin America[1].

4. Pipeline Development

UCB's robust pipeline, with 12 clinical programs ongoing spanning 10 different medicines, demonstrates its commitment to future growth. The company obtained 14 approvals across six patient populations in key regions (U.S., EU, and Japan) since January 2023[6].

Competitive Landscape

While UCB has established a strong position in its core therapeutic areas, it faces competition from several major pharmaceutical companies:

  1. Pfizer
  2. Novartis
  3. Amgen
  4. Regeneron Pharmaceuticals
  5. Vertex Pharmaceuticals

These competitors have significant resources and established market positions, making it crucial for UCB to maintain its focus on innovation and strategic partnerships to stay competitive.

Future Outlook

UCB's future looks promising, with analysts projecting revenue growth at a compound annual growth rate (CAGR) of 6-8% through 2025[1]. This growth is expected to be driven by:

  1. Launch of new products
  2. Expansion of existing product lines
  3. Continued focus on R&D
  4. Strategic partnerships and collaborations

Key Growth Drivers

  1. Bimekizumab: UCB's upcoming product for treating psoriasis is expected to contribute significantly, with estimated revenue projections of €400 million by 2025[1].

  2. Strategic Partnerships: Collaborations like the one with Provention Bio are expected to generate potential revenues exceeding €200 million from shared developments[1].

  3. Geographical Expansion: Continued growth in emerging markets is expected to contribute to UCB's overall revenue growth.

Challenges and Risks

Despite its strong position, UCB faces several challenges and risks:

  1. Intense Competition: The pharmaceutical industry is highly competitive, with constant pressure to innovate and differentiate.

  2. Regulatory Challenges: Changes in regulations can impact drug approval processes and market entry.

  3. Product Portfolio Dependency: UCB relies heavily on a few key products for revenue, with 70% of the company's sales in 2022 coming from its leading product, Cimzia[1].

  4. High R&D Costs: The significant investment in R&D (32% of total revenue in 2022) carries the risk of unsuccessful product development[1].

  5. Supply Chain Disruptions: Global supply chain issues continue to pose risks, with UCB reporting delays in raw material procurement that potentially impact product availability[1].

Key Takeaways

  1. UCB has established a strong market position in neurology and immunology, with a 5.1% market share in its core therapeutic areas.

  2. The company's focus on innovation, strategic partnerships, and patient-centric solutions has driven its success.

  3. UCB's robust product portfolio and pipeline, coupled with its strong financial performance, position it well for future growth.

  4. The company faces challenges from intense competition, regulatory pressures, and product portfolio dependency.

  5. Analysts project a 6-8% CAGR for UCB through 2025, driven by new product launches and market expansions.

UCB's strategic focus on niche markets, commitment to innovation, and global expansion efforts position it as a formidable player in the pharmaceutical industry. While challenges exist, the company's strong foundation and forward-looking strategies suggest a promising future in the competitive pharmaceutical landscape.

FAQs

  1. Q: What are UCB's main therapeutic focus areas? A: UCB primarily focuses on neurology and immunology, developing innovative treatments for severe diseases in these areas.

  2. Q: How much does UCB invest in Research and Development? A: In 2022, UCB invested €1.29 billion in R&D, representing about 32% of its total revenue.

  3. Q: What is UCB's market share in its core therapeutic areas? A: UCB holds approximately 5.1% market share in its primary focus areas of neurology and immunology.

  4. Q: What are some of UCB's key products? A: Some of UCB's key products include Cimzia, Vimpat, Keppra, Neupro, Briviact, Bimzelx, Evenity, Nayzilam, and Fintepla.

  5. Q: What is the projected revenue growth for UCB through 2025? A: Analysts project UCB's revenue to grow at a compound annual growth rate (CAGR) of 6-8% through 2025.

Sources cited:

  1. https://dcfmodeling.com/blogs/health/ucbbr-financial-health
  2. https://www.ucb.com/about-ucb
  3. https://www.mbaskool.com/swot-analysis/pharmaceuticals-and-healthcare/3317-ucb-pharmaceuticals.html
  4. https://www.ucb.com/newsroom/press-releases/article/ucb-on-growth-path-for-a-decade-plus
  5. https://www.morningstar.com/stocks/xbru/ucb/quote
Last updated: 2025-02-12

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.